MYMD-1 / Isomyosamine
phase 2Reduce chronic inflammation and treat aging-related sarcopenia/frailty, including muscle loss and recovery in older adults after hip or thigh bone fractures; also positioned for rheumatoid arthritis and other inflammatory conditions.
Orally available next-generation TNF-alpha inhibitor/immunometabolic regulator that can cross the blood-brain barrier and targets inflammatory cytokines including TNF-alpha and IL-6; evaluated in Phase I safety/PK studies and Phase II clinical studies in sarcopenia/frailty.
Phase II clinical study of Isomyosamine for reducing inflammation and treating muscle loss in older adults after hip or thigh bone fractures, published 2025-05-01.
Preclinical publications report MYMD-1 ameliorated experimental autoimmune encephalomyelitis and autoimmune thyroiditis via suppression of Th1 responses and TNF-alpha release. Supplied material does not include clinical efficacy results.